Pharma industry agrees need of preferential treatments on biologics, but HIRA says “Well…”

Which health insurance standards should biologics, which are evaluated as innovative treatment, meet?

The pharmaceutical industry believes that it is necessary to give preference to Korean new drugs and biologics for global expansion, but the government has been careful over the ‘insurance benefits’ even though planning to promote the industry as a future growth engine.

The issue was also dis...